Opinion|Videos|August 23, 2024
Safety and Efficacy of Tebentafusp
Author(s)Nathan L. Scott, M.D., Melody Burchett
Nathan L. Scott, M.D., discusses the safety and efficacy of tebentafusp. This program was made possible with support from Immunocore.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please discuss recent updates for tebentafusp.
- Have you had clinical experience with tebentafusp? If so, please comment.
- What mitigation strategies do you implement to manage side effects?
- What do patients need to understand about the black box warning about cytokine release syndrome?
Advertisement
Related to this article
A nurse practitioner discusses how an app provides information on cancer treatments, potential side effects and preparing for medical appointments.
Final KEYNOTE-564 data show Keytruda after kidney cancer surgery lowered the risk of death by 30%. Dr. Toni Choueiri explains what it means for patients.
HealthCare.gov open enrollment runs Nov. 1, 2026, to Jan. 15, 2027, and the 2027 out-of-pocket ceiling rises to $12,000. Here's what people with cancer should check before picking a plan.
After nearly a year of chemotherapy, a patient with stage 4 pancreatic cancer describes daily life and side effects on Rasonque (daraxonrasib).
For Lung Cancer Awareness Month, answers to common patient questions about biomarker testing in non-small cell lung cancer: which gene changes doctors look for, blood vs. tissue tests, insurance and retesting.
A physician emphasized how emotional support, reliable health information and caregiver involvement can encourage men to take a more proactive approach to prostate cancer screening and care.
After a blood cancer diagnosis, a survivor reflects on the close friends who let her be herself and asks whether she is the kind of friend she once needed.
From a new chemotherapy combination to the first RAS-targeted pill, here's what five years of pancreatic cancer approvals mean for patients.
Advertisement
Advertisement